No.
The trial was stopped in 2002 after the invasive breast cancer diagnosis rate crossed a prespecified monitoring boundary, combined with an overall index suggesting risks outweighed benefits across several outcomes together. All-cause mortality was not affected in the original report, and it remained unaffected across 18 years of cumulative follow-up for both the combined and estrogen-alone regimens. Later follow-up did find a breast cancer mortality signal specifically in the combined-therapy group at 11 years, but by 20-plus years that mortality difference was no longer statistically significant, even though the increase in diagnoses persisted.
Both camps agree the trial stopped on diagnosis and a composite index, not on a mortality finding. Where they differ is how much weight to give the later, borderline mortality signal in the combined-therapy group at 11 years, which had faded by 20-plus years.
What the research shows, and which source each finding rests on
The trial was stopped early after the invasive breast cancer test statistic crossed the prespecified stopping boundary and the global index suggested risks exceeded benefits; it was not stopped due to increased deaths.
The 2002 report found all-cause mortality was not affected (HR 0.98); the risks-exceed-benefits conclusion came from a global index of several outcomes, not from any excess in deaths.
Neither WHI regimen changed all-cause mortality over 18 years of cumulative follow-up. At 11 years, combined therapy showed a breast cancer mortality increase that reached borderline significance (HR 1.96, P=.049); by 20-plus years that mortality excess was no longer statistically significant (HR 1.35, P=.11), even as the increase in diagnoses persisted.
Where the real disagreement is
Each position is shown with its own sources. A position listed here is not necessarily the accepted view.
the mortality story shows the risk was overstated
Sharon Malone, Avrum Bluming, and other corpus clinicians
No credible mortality increase was found at the time of the announcement, and the modest mortality signal seen at 11 years in the combined-therapy arm did not hold up statistically by 20-plus years, while diagnoses alone drove the initial panic.
the diagnosis excess and the interim mortality signal were both real findings that should not be waved away
the WHI investigators
The 11-year mortality signal, even if not confirmed at 20-plus years, along with the more advanced, node-positive nature of combined-therapy cancers, are real findings from a rigorous trial and are part of the honest picture, not a false alarm.
What would settle it: Longer, more granular follow-up data on breast-cancer-specific mortality by regimen; the 20-plus year data are the longest currently available and show a persisting diagnosis increase without a statistically confirmed mortality increase.
What is really going on here
- Is the risk we are discussing incidence (getting diagnosed) or death? What happened to mortality in the trials?
- Why was the trial actually stopped, according to the trial's own stopping rules?
Questions for your doctor
- Does the evidence distinguish between an increased chance of diagnosis and an increased chance of dying from breast cancer?
- How does breast cancer mortality data factor into your recommendation for me?
- What monitoring would we do if I started hormone therapy?
Questions with no answer yet
Why did the borderline 11-year breast cancer mortality signal in the combined-therapy group fade to non-significance by 20-plus years, and does that mean it was never real, or that longer follow-up simply diluted a real but small effect?
Partly studiedWhat is known: At 11 years, combined therapy showed a mortality increase that reached only borderline statistical significance. By 20-plus years that mortality difference was no longer statistically significant, even though the increase in diagnoses persisted throughout.
What would test it: Continued long-term follow-up of the same trial cohort, or a pooled analysis combining this trial with other combined-therapy cohorts, to see whether the mortality signal reappears with a larger combined sample.
Does the trial's stopping rule, built around a composite index of several different outcomes, actually reflect what matters most to an individual woman deciding about hormone therapy?
Not directly studied yetNo research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.
What is known: The trial was stopped using a prespecified statistical boundary on breast cancer diagnoses plus a global index that weighted very different outcomes, such as a hip fracture and an early treatable cancer, as equivalent events. This method was built for trial monitoring, not for representing any one woman's personal values about which risks matter most.
What would test it: A decision-analysis study using individual patient preferences and utilities, rather than a single combined index, to see whether it changes which outcome would be considered decisive.
Sources
- 1.Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.Writing Group for the WHI Investigators (Rossouw JE et al.), JAMA 2002 · Randomised trial
- 2.Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women.Chlebowski RT et al., JAMA 2010 · Randomised trial
- 3.Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials.Chlebowski RT et al., JAMA 2020 · Randomised trial
The letter grades the type of study behind a claim, not the answer itself.
This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.
You are not imagining it
In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.
Start Free MappingRelated questions
- Does hormone therapy cause breast cancer?
- What does it actually mean that hormone therapy increases breast cancer risk by 26 percent?
- Is estrogen-only hormone therapy safer for breast cancer risk than combined estrogen-progestin therapy?
- Is bioidentical or micronized progesterone safer for breast cancer risk than the older synthetic progestins?
- Can breast cancer survivors take hormone therapy for their menopause symptoms?
- Is vaginal estrogen safe if I've had breast cancer, especially if I'm on an aromatase inhibitor?
- Back to topic: Hormone therapy and breast cancer